FASEB J. Pierce now sold as Thermo Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by RUDLING, M.
Right arrow Articles by ANGELIN, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by RUDLING, M.
Right arrow Articles by ANGELIN, B.
(The FASEB Journal. 2001;15:1350-1356.)
© 2001 FASEB

Growth hormone reduces plasma cholesterol in LDL receptor-deficient mice

MATS RUDLING1 and BO ANGELIN

Metabolism Unit, Center for Metabolism and Endocrinology, Department of Medicine, and Molecular Nutrition Unit, Center for Nutrition and Toxicology, Novum, Karolinska Institute at Huddinge University Hospital, S-141 86, Stockholm, Sweden

1Correspondence: CME, M63, Huddinge University Hospital, S-141 86 Stockholm, Sweden. E-mail: mats.rudling{at}cnt.ki.se

Growth hormone (GH) has pleiotropic effects on cholesterol and lipoprotein metabolism. Pituitary GH is important for the normal regulation of hepatic LDL receptors (LDLR), for the enzymatic activity of bile acid regulatory cholesterol 7{alpha}-hydroxylase (C7{alpha}OH), and for the maintenance of resistance to dietary cholesterol. The present study aimed to determine whether GH has beneficial effects on plasma lipids and hepatic cholesterol metabolism in mice devoid of LDLR. Compared with wild-type controls, LDLR-deficient mice had ~250% elevated plasma total cholesterol and ~50% increased hepatic cholesterol levels; hepatic HMG CoA reductase activity was reduced by 70%, whereas C7{alpha}OH activity was increased by 40%. In LDLR mice, GH infusion reduced plasma cholesterol and triglycerides up to 40%, whereas HMG CoA reductase and C7{alpha}OH activities were stimulated by ~ 50% and 110% respectively. GH also stimulated HMG CoA reductase and C7{alpha}OH activities in control mice, whereas hepatic LDLR and plasma lipoproteins were unchanged. The effects of cholestyramine and atorvastatin on C7{alpha}OH in LDLR-deficient mice were potentiated by GH, and this was associated with a further reduction in plasma cholesterol. GH treatment reduces plasma cholesterol and triglycerides and stimulates C7{alpha}OH activity in mice devoid of LDLR, particularly in combination with resin or statin treatment. The potential of GH therapy in patients with homozygous familial hypercholesterolemia should be evaluated.—Rudling, M., Angelin, B. Growth hormone reduces plasma cholesterol in LDL receptor-deficient mice.


Key Words: hypercholesterolemia • familial • cholesterol 7{alpha}-monooxygenase • statins • resins




This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. Galman, M. Matasconi, L. Persson, P. Parini, B. Angelin, and M. Rudling
Age-induced hypercholesterolemia in the rat relates to reduced elimination but not increased intestinal absorption of cholesterol
Am J Physiol Endocrinol Metab, September 1, 2007; 293(3): E737 - E742.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. Johansson, M. Rudling, T. S. Scanlan, T. Lundasen, P. Webb, J. Baxter, B. Angelin, and P. Parini
Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice
PNAS, July 19, 2005; 102(29): 10297 - 10302.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. Matasconi, B. Angelin, and M. Rudling
Pituitary control of lipoprotein and bile acid metabolism in male rats: growth hormone effects are not mediated by prolactin
Am J Physiol Endocrinol Metab, July 1, 2004; 287(1): E114 - E119.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. Lind, M. Rudling, S. Ericsson, H. Olivecrona, M. Eriksson, B. Borgstrom, G. Eggertsen, L. Berglund, and B. Angelin
Growth Hormone Induces Low-Density Lipoprotein Clearance but not Bile Acid Synthesis in Humans
Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 349 - 356.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. B. Twickler, M. J. M. Cramer, G. M. Dallinga-Thie, M. J. Chapman, D. W. Erkelens, and H. P. F. Koppeschaar
Adult-Onset Growth Hormone Deficiency: Relation of Postprandial Dyslipidemia to Premature Atherosclerosis
J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2479 - 2488.
[Full Text] [PDF]

Home page
 J. Lipid Res.Home page
C. Galman, I. Arvidsson, B. Angelin, and M. Rudling
Monitoring hepatic cholesterol 7{alpha}-hydroxylase activity by assay of the stable bile acid intermediate 7{alpha}-hydroxy-4-cholesten-3-one in peripheral blood
J. Lipid Res., April 1, 2003; 44(4): 859 - 866.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
H. Gullberg, M. Rudling, C. Salto, D. Forrest, B. Angelin, and B. Vennstrom
Requirement for Thyroid Hormone Receptor {beta} in T3 Regulation of Cholesterol Metabolism in Mice
Mol. Endocrinol., August 1, 2002; 16(8): 1767 - 1777.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by The Federation of American Societies for Experimental Biology.